急慢性疼痛生物标志物的创新:提升诊断与个体化治疗
本文综述了急慢性疼痛生物标志物的研究进展,涵盖影像学、分子、感觉和神经生理学方法,强调整合心理社会因素的多模式复合策略可提升慢性疼痛管理的精准性和适用性。分子标志物(如细胞因子、蛋白质组学和代谢物)具有诊断和预后潜力,但需广泛验证。未来方向包括复合标志物特征、人工智能及整合入临床决策支持系统。
要点
- 影像学和神经生理学技术可揭示疼痛相关结构与功能异常。
- 分子标志物有诊断和预后潜力,但尚需大规模验证。
- 整合心理社会因素的复合多模式策略可提高标志物精准性。
核心结论
- 生物标志物有望变革急慢性疼痛管理,改善诊断、治疗个体化和患者结局。
研究设计与样本
- 本文为综述,综合了近期关于急慢性疼痛生物标志物识别与验证的研究进展。
主要发现
- MRI和正电子发射断层扫描可提供疼痛相关结构和功能异常的信息。
- 脑电图和脑磁图等电生理方法可评估疼痛神经轴的功能处理障碍。
- 细胞因子、蛋白质组学和代谢物等分子标志物具有诊断和预后潜力,但需广泛验证。
- 整合心理社会因素的复合多模式策略可提高慢性疼痛管理中标志物的精准性和适用性。
临床怎么用
- 将生物标志物与心理社会因素整合入临床实践,可制定个体化治疗策略并改善患者结局。
- 未来可将生物标志物特征整合入临床决策支持系统以辅助疼痛管理。
局限性
- 分子标志物需广泛验证,且需严格的验证和标准化工作以确保临床实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pain affects millions worldwide, posing significant challenges in diagnosis and treatment. Despite advances in understanding pain mechanisms, there remains a critical need for validated biomarkers to enhance diagnosis, prognostication, and personalized therapy. This review synthesizes recent advancements in identifying and validating acute and chronic pain biomarkers, including imaging, molecular, sensory, and neurophysiological approaches. We emphasize the emergence of composite, multimodal strategies that integrate psychosocial factors to improve the precision and applicability of biomarkers in chronic pain management. Neuroimaging techniques like MRI and positron emission tomography provide insights into structural and functional abnormalities related to pain, while electrophysiological methods like electroencepholography and magnetoencepholography assess dysfunctional processing in the pain neuroaxis. Molecular biomarkers, including cytokines, proteomics, and metabolites, offer diagnostic and prognostic potential, though extensive validation is needed. Integrating these biomarkers with psychosocial factors into clinical practice can revolutionize pain management by enabling personalized treatment strategies, improving patient outcomes, and potentially reducing healthcare costs. Future directions include the development of composite biomarker signatures, advances in artificial intelligence, and biomarker signature integration into clinical decision support systems. Rigorous validation and standardization efforts are also necessary to ensure these biomarkers are clinically useful. Large-scale collaborative research will be vital to driving progress in this field and implementing these biomarkers in clinical practice. This comprehensive review highlights the potential of biomarkers to transform acute and chronic pain management, offering hope for improved diagnosis, treatment personalization, and patient outcomes.
引用
- Mackey S, Aghaeepour N, Gaudilliere B, et al. Innovations in acute and chronic pain biomarkers: enhancing diagnosis and personalized therapy. Reg Anesth Pain Med. 2025. PMID: 39909549. doi:10.1136/rapm-2024-106030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。